Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

HIV-associated Hodgkin's disease.

T Powles¹, M Bower

¹Department of Oncology, Chelsea and Westminster Hospital, London, UK.

International Journal of STD & AIDS

|September 16, 2000

Summary

Hodgkin's disease (HD) is more common in people with HIV, presenting with distinct characteristics and poorer outcomes. HIV significantly impacts HD prognosis, leading to lower response and higher relapse rates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation.

ESMO open·2026

Same author

A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma).

ESMO open·2026

Same author

Higher rates of immune-related adverse events in circulating tumor DNA (ctDNA)-negative patients following adjuvant checkpoint inhibitor therapy.

ESMO open·2026

Same author

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

Nivolumab plus gemcitabine-cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial.

ESMO open·2026

Same author

Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Area of Science:

Oncology
Infectious Diseases
Virology

Background:

Hodgkin's disease (HD) incidence and presentation differ in individuals with Human Immunodeficiency Virus (HIV).
Epstein-Barr virus (EBV) association is more frequent in HIV-positive HD patients.
Specific histological subtypes, including mixed cellularity and lymphocyte-depleted, are more prevalent in this population.

Purpose of the Study:

To elucidate the unique epidemiological and clinical features of Hodgkin's disease in the context of HIV infection.
To compare prognostic factors and outcomes of HD in HIV-positive individuals versus the general population.

Main Methods:

Comparative analysis of clinical presentation, histology, and outcomes.
Assessment of prognostic variables in HIV-associated HD.
Review of treatment response rates and survival data.

Main Results:

HIV-associated HD frequently presents at advanced stages with extranodal involvement.
Prognosis is predominantly influenced by HIV status rather than HD-specific factors.
Patients with HIV experience lower treatment response rates, increased infectious complications, and diminished overall survival.

Conclusions:

Hodgkin's disease in people with HIV exhibits distinct epidemiological and clinical patterns.
HIV significantly worsens the prognosis of Hodgkin's disease, underscoring the need for tailored management strategies.

Related Experiment Videos